Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 11/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706801 | 1.00 | S1PR1 (0.46) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL9714443 | 0.87 | CNR1 (0.39) | S1PR1CNR1ADRA1DADRA1AADRA2B | |
| SCHEMBL104898 | 0.83 | GLA (0.46) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL1343700 | 0.83 | GSK3B (0.46) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL23056923 | 0.80 | GLA (0.44) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL1719895 | 0.80 | GLA (0.44) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL4095529 | 0.80 | ENPP2 (0.46) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL22435570 | 0.80 | GLA (0.44) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL320196 | 0.80 | ENPP2 (0.46) | S1PR1GLACNR1ADRA1DADRA1A | |
| SCHEMBL16959032 | 0.80 | GLA (0.44) | S1PR1GLACNR1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| CN-101193898-B | Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives | ASTRAZENECA AB | 2010-12-01 | — | — | CN | disclosed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
| CN-101193898-A | Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives | ASTRAZENECA AB (SE) | 2008-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | CX3CR1, CCR2, CXCR3 | S1PR1 112/4885GLA 4723/4885CNR1 98/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | S1PR1 213/4885GLA 4473/4885CNR1 41/4885 |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | CX3CR1, CCR2, CCR5 | S1PR1 208/4885GLA 4756/4885CNR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.